{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:38:14Z","timestamp":1792985894995,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>In Graves' disease (GD), autoantibodies to the thyroid stimulating hormone receptor (TSHR) cause hyperthyroidism. The condition is often associated with eye signs including proptosis, oedema, and diplopia (collectively termed Graves' orbitopathy [GO]). The safety profile of K1\u201070<jats:sup>TM<\/jats:sup> (a human monoclonal TSHR specific autoantibody, which blocks ligand binding and stimulation of the receptor) in patients with GD was evaluated in a phase I clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Study Design<\/jats:title><jats:p>Eighteen GD patients stable on antithyroid drug medication received a single intramuscular (IM) or intravenous (IV) dose of K1\u201070<jats:sup>TM<\/jats:sup> during an open label phase I ascending dose, safety, tolerability, pharmacokinetic and pharmacodynamic (PD) study. Immunogenic effects of K1\u201070<jats:sup>TM<\/jats:sup> were also determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>K1\u201070<jats:sup>TM<\/jats:sup> was well\u2010tolerated in all subjects at all doses and no significant immunogenic response was observed. There were no deaths or serious adverse events. Increased systemic exposure to K1\u201070<jats:sup>TM<\/jats:sup> was observed following a change to IV dosing, indicating this was the correct dosage route. Expected PD effects occurred after a single IM dose of 25\u2009mg or single IV dose of 50\u2009mg or 150\u2009mg with fT3, fT4, and TSH levels progressing into hypothyroid ranges. There were also clinically significant improvements in symptoms of both GD (reduced tremor, improved sleep, improved mental focus, reduced toilet urgency) and GO (reduced exophthalmos measurements, reduced photosensitivity).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>K1\u201070<jats:sup>TM<\/jats:sup> was safe, well tolerated and produced the expected PD effects with no immunogenic responses. It shows considerable promise as a new drug to block the actions of thyroid stimulators on the TSHR.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.14681","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T04:37:36Z","timestamp":1643344656000},"page":"878-887","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["TSH receptor specific monoclonal autoantibody K1\u201070<sup>TM<\/sup> targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy\u2014Results from a phase I clinical trial"],"prefix":"10.1111","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2623-1128","authenticated-orcid":false,"given":"Jadwiga","family":"Furmaniak","sequence":"first","affiliation":[{"name":"AV7 Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"},{"name":"RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Sanders","sequence":"additional","affiliation":[{"name":"AV7 Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"},{"name":"RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sanders","sequence":"additional","affiliation":[{"name":"RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rees Smith","sequence":"additional","affiliation":[{"name":"AV7 Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"},{"name":"RSR Limited, FIRS Laboratories, Parc Ty Glas Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-9-1-106"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1559648"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa022"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13908"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0418"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443828"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1045-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2010.03831.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0552"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.5.9497"},{"key":"e_1_2_10_12_1","first-page":"28","article-title":"Teprotumumab\u2014interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","author":"Winn BJ","year":"2021","journal-title":"Ophthalmology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0036"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13317-011-0025-9"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-019-0121-9"},{"key":"e_1_2_10_16_1","unstructured":"WMA\u2010The World Medical Association\u2010WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects.https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects. accessed 12 Aug 2021."},{"key":"e_1_2_10_17_1","unstructured":"ICH E6 (R2) Good clinical practice. European Medicines Agency2018.https:\/\/www.ema.europa.eu\/en\/ich-e6-r2-good-clinical-practice. accessed 12 Aug 2021."},{"key":"e_1_2_10_18_1","unstructured":"AV7 Limited. K1\u201070 \u2010 A Phase I Single Ascending Intramuscular Dose or Single Ascending Intravenous Dose Safety Tolerability Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease. Report No.: NCT02904330.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02904330. accessed 10 Aug 2021."},{"key":"e_1_2_10_19_1","unstructured":"Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administrationhttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. accessed 28 Jul 2021."},{"key":"e_1_2_10_20_1","unstructured":"RSR Limited In Vitro Diagnostics. Manufacturer of Medical Diagnostic Devices Reagents & Kits for the Test and Diagnosis of Autoimmune Diseases.http:\/\/www.rsrltd.comaccessed 22 Jul 2021"},{"key":"e_1_2_10_21_1","unstructured":"https:\/\/www.regulations.gov\/docket\/FDA-2009-D-0539. accessed 25 Aug 2021. \u2018Immunogenicity Testing of Therapeutic Protein Products \u2013 Developing and Validating Assays for Anti\u2010Drug Antibody Detection\u2019."},{"key":"e_1_2_10_22_1","unstructured":"Hypothyroidism. British Thyroid Foundation.https:\/\/www.btf-thyroid.org\/hypothyroidism-leaflet. accessed 12 Aug 2021."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-019-0345-9"},{"issue":"10","key":"e_1_2_10_24_1","first-page":"1597","article-title":"Blocking the thyrotropin receptor with K1\u201070 in a patient with follicular thyroid cancer, Graves' disease, and Graves' ophthalmopathy","volume":"31","author":"Ryder M","year":"2021","journal-title":"Thyroid"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1580"},{"key":"e_1_2_10_26_1","unstructured":"FDA Approves TEPEZZATM (teprotumumab\u2010trbw) for the Treatment of Thyroid Eye Disease (TED). Horizon Therapeutics plc.https:\/\/ir.horizontherapeutics.com\/news-releases\/news-release-details\/fda-approves-tepezzatm-teprotumumab-trbw-treatment-thyroid-eye. accessed 2 Jul 2021."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00076-0"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001995"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/01945998211004240"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/00034894211042740"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242153"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510700"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14681","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cen.14681","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.14681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:04:17Z","timestamp":1692972257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.14681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/cen.14681"],"URL":"https:\/\/doi.org\/10.1111\/cen.14681","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,6]]},"assertion":[{"value":"2021-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}